UK drugs regulator looks to partner with Australia and Canada after Brexit

The UK MHRA is considering partnerships with global markets such as Canada and Australia after Brexit to make the UK more attractive to drugmakers to launch a product.

The plan would mean a product approved by the UK would automatically gain market access to these countries under a special agreement said Andrew Gregory, deputy policy lead at MHRA.

Gregory said the U.K. was exploring links with Australia, Canada, Switzerland and other countries through existing collaborations such as the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.

These countries are already working on a model of “decentralized procedure” for approval that would mean only one country assesses the drug, a similar process to the EMA.

Read the full article here.

Tagged with

Published on 15. July 2017 in News UK